Recent 8-K filings for RGBP

• March 4, 2026, 6:59 PM ET other material materiality 0.75 negative item 3.02

  Regen Biopharma issues 77.85M shares to settle $68,723 in debt and fees

  Issued 77,849,847 common shares between Feb 4-27, 2026 for $53,474 principal, $4,249 interest, $11,000 fees.

• February 2, 2026, 6:59 PM ET other material materiality 0.85 negative item 3.02

  Regen Biopharma issues 21.4M shares in Jan 2026 for $69,550, massive dilution

  On Jan 15, 2026, issued 5,000,000 shares to satisfy $11,449 principal + $8,101 interest on convertible debt.

• October 3, 2025, 7:59 PM ET other material materiality 0.75 negative item 1.01item 8.01item 9.01

  Regen BioPharma issues 40M shares to CEO and consultant for Phase I trial; shares vest on trial success

  Issued 20M shares to CEO David Koos for services in planned Phase I trial of HemaXellerate; shares vest upon trial completion.

• August 1, 2025, 7:59 PM ET debt materiality 0.60 neutral item 1.01item 3.02item 9.01

  Regen Biopharma enters $130K convertible note financing with CFI Capital

  Issued a 6% convertible promissory note for $130,000 principal; $13,000 original issue discount, net proceeds $117,000.

• June 11, 2025, 7:59 PM ET other material materiality 0.70 neutral item 3.02item 9.01

  Regen Biopharma issues 10M shares to CEO in settlement of $50K accrued salary

  Issued 10,000,000 common shares to CEO David R. Koos as settlement for $50,000 of accrued unpaid salary.

• May 13, 2025, 7:59 PM ET other material materiality 0.70 negative item 4.02

  Regen Biopharma restates FY2024 financials; prior statements not reliable

  Non-reliance on unaudited FY2024 financials filed Nov 20, 2024; share compensation and derivative liability corrected.

• April 7, 2025, 7:59 PM ET other material materiality 0.60 neutral item 4.01

  Regen Biopharma dismisses Bush & Associates, engages BCRG Group as new auditor

  Dismissed Bush and Associates CPA LLC as independent auditor effective March 31, 2025.

• November 29, 2024, 6:59 PM ET earnings materiality 0.85 negative item 2.02item 9.01

  Regen Biopharma FY2024 net loss $867k, revenue $237k; cash only $716

  Total revenues of $236,560 (incl. $110k related party); operating loss of $418,189.

• September 13, 2024, 7:59 PM ET debt materiality 0.65 negative item 1.01item 9.01

  Regen Biopharma issues $250K promissory note to Coventry; $25K OID, convertible on default

  Principal amount $250K; original issue discount $25K, net proceeds $200K.

• May 10, 2024, 7:59 PM ET other material materiality 0.60 negative item 4.01 ◈ Auditor Changes

  Regen Biopharma dismisses auditor BF Borgers due to SEC cease-and-desist order

  BF Borgers CPA PC dismissed as independent auditor effective May 10, 2024, following SEC order of May 3, 2024.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event other_material

0 positive 8 negative 10 neutral

source · RGBP on sec.gov